A clinical trial reports that cancer “jabs” may destroy entire head and neck tumours in some patients whose cancers do not respond to existing treatments. Both outlets focus on results described as notable for treatment-resistant cases, indicating that the therapy can drive major tumour shrinkage, including disappearance of whole tumours in reported instances. The coverage also provides epidemiological context, stating that head and neck cancer is the sixth most common cancer worldwide and that about 12,800 people in the UK are diagnosed each year. While the articles agree on the headline finding—that the trial’s vaccine approach shows activity against tumours in patients with limited treatment options—the available excerpts do not specify further details such as the trial size, study design, exact response rates, duration of follow-up, or possible side effects. The reports present the findings as trial evidence supporting potential effectiveness of the treatment in difficult-to-treat disease, alongside the broader public-health relevance of head and neck cancer.